Patents by Inventor Andrew Cridland

Andrew Cridland has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Pyridazine derivatives as RORc modulators
    Patent number: 11008312
    Abstract: Compounds of formula I: or pharmaceutical salts thereof, wherein m, n, p, q A, B, R1, R2, R3, R4, R5, R6 and R7 are as defined herein. Also disclosed are methods of making the compounds and using the compounds for treatment of inflammatory diseases such as arthritis.
    Type: Grant
    Filed: April 30, 2019
    Date of Patent: May 18, 2021
    Assignee: Genentech, Inc.
    Inventors: Sarah M. Bronner, James J. Crawford, Andrew Cridland, Patrick Cyr, Benjamin Fauber, Emanuela Gancia, Alberto Gobbi, Christopher Hurley, Jonathan Killen, Wendy Lee, Olivier Rene, Monique Bodil Van Niel, Stuart Ward, Paul Winship, Jason Zbieg
  • Oxadiazolones as transient receptor potential channel inhibitors
    Patent number: 10913742
    Abstract: The invention relates to compounds of formula (I): and pharmaceutically acceptable salts thereof. In addition, the present invention relates to methods of manufacturing and methods of using the compounds of formula (I) as well as pharmaceutical compositions containing such compounds. The compounds may be useful in treating diseases and conditions mediated by TRPA1, such as respiratory disorders or pain.
    Type: Grant
    Filed: May 23, 2019
    Date of Patent: February 9, 2021
    Assignee: Genentech, Inc.
    Inventors: Huifen Chen, Daniel Shore, Elisia Villemure, Matthew Volgraf, Baihua Hu, Aijun Lu, Andrew Cridland, Stuart Ward, Francis Beaumier, Martin Dery, Robin Larouche-Gauthier
  • Pyridazine derivatives as RORc modulators
    Patent number: 10487068
    Abstract: Compounds of formula I: or pharmaceutical salts thereof, wherein m, n, A, R1, R2, R3, R4 and R5 are as defined herein. Also disclosed are methods of making the compounds and using the compounds for treatment of inflammatory diseases such as arthritis.
    Type: Grant
    Filed: November 1, 2017
    Date of Patent: November 26, 2019
    Assignee: Genentech, Inc.
    Inventors: Benjamin Fauber, Monique Bodil van Niel, Andrew Cridland, Christopher Hurley, Jonathan Killen, Stuart Ward
  • OXADIAZOLONES AS TRANSIENT RECEPTOR POTENTIAL CHANNEL INHIBITORS
    Publication number: 20190284189
    Abstract: The invention relates to compounds of formula (I): and pharmaceutically acceptable salts thereof. In addition, the present invention relates to methods of manufacturing and methods of using the compounds of formula (I) as well as pharmaceutical compositions containing such compounds. The compounds may be useful in treating diseases and conditions mediated by TRPA1, such as respiratory disorders or pain.
    Type: Application
    Filed: May 23, 2019
    Publication date: September 19, 2019
    Applicant: Genentech, Inc.
    Inventors: Huifen CHEN, Daniel SHORE, Elisia VILLEMURE, Matthew VOLGRAF, Baihua HU, Aijun LU, Andrew CRIDLAND, Stuart WARD, Francis BEAUMIER, Martin DERY, Robin LAROUCHE-GAUTHIER
  • PYRIDAZINE DERIVATIVES AS RORc MODULATORS
    Publication number: 20190263794
    Abstract: Compounds of formula I: or pharmaceutical salts thereof, wherein m, n, p, q A, B, R1, R2, R3, R4, R5, R6 and R7 are as defined herein. Also disclosed are methods of making the compounds and using the compounds for treatment of inflammatory diseases such as arthritis.
    Type: Application
    Filed: April 30, 2019
    Publication date: August 29, 2019
    Applicant: Genentech, Inc.
    Inventors: Sarah M. Bronner, James J. Crawford, Andrew Cridland, Patrick Cyr, Benjamin Fauber, Emanuela Gancia, Alberto Gobbi, Christopher Hurley, Jonathan Killen, Wendy Lee, Olivier Rene, Monique Bodil Van Niel, Stuart Ward, Paul Winship, Jason Zbieg
  • Pyridazine derivatives as RORc modulators
    Patent number: 10280144
    Abstract: Compounds of formula I: or pharmaceutical salts thereof, wherein m, A, X, Y, Z, R1, R2, R3, R4 and R5 are as defined herein. Also disclosed are methods of making the compounds and using the compounds for treatment of inflammatory diseases such as arthritis.
    Type: Grant
    Filed: November 1, 2017
    Date of Patent: May 7, 2019
    Assignee: Genentech, Inc.
    Inventors: Benjamin Fauber, James J. Crawford, Sarah M. Bronner, Monique Bodil van Niel, Andrew Cridland, Emanuela Gancia, Christopher Hurley, Jonathan Killen, Stuart Ward
  • PYRIDAZINE DERIVATIVES AS RORc MODULATORS
    Publication number: 20180222882
    Abstract: Compounds of formula I: or pharmaceutical salts thereof, wherein m, n, A, R1, R2, R3, R4 and R5 are as defined herein. Also disclosed are methods of making the compounds and using the compounds for treatment of inflammatory diseases such as arthritis.
    Type: Application
    Filed: November 1, 2017
    Publication date: August 9, 2018
    Applicant: Genentech, Inc.
    Inventors: Benjamin Fauber, Monique Bodil van Niel, Andrew Cridland, Christopher Hurley, Jonathan Killen, Stuart Ward
  • Pyridazine derivatives as RORc modulators
    Patent number: 9994551
    Abstract: Compounds of formula I: or pharmaceutical salts thereof, wherein R1, R2, R3 and R4 are as defined herein. Also disclosed are methods of making the compounds and using the compounds for treatment of inflammatory diseases such as arthritis.
    Type: Grant
    Filed: November 1, 2017
    Date of Patent: June 12, 2018
    Assignee: Genentech, Inc.
    Inventors: Benjamin Fauber, Monique Bodil van Niel, Andrew Cridland, Christopher Hurley, Jonathan Killen, Stuart Ward, Paul Winship
  • Pyridazine derivatives as RORc modulators
    Patent number: 9981916
    Abstract: Compounds of the formula I: or a pharmaceutical salt thereof, wherein X, Ar1, R1, R2, R3, R4, R5, R6 and R7 are as defined herein. Also disclosed are methods of making the compounds and using the compounds for treatment of inflammatory diseases such as arthritis.
    Type: Grant
    Filed: November 5, 2014
    Date of Patent: May 29, 2018
    Assignee: Genentech, Inc.
    Inventors: Monique Bodil van Niel, Andrew Cridland, Benjamin Fauber, Alberto Gobbi, Christopher Hurley, David Hurst, Jonathan Killen, Robert Maxey, Stuart Ward
  • PYRIDAZINE DERIVATIVES AS RORc MODULATORS
    Publication number: 20180072683
    Abstract: Compounds of formula I: or pharmaceutical salts thereof, wherein m, A, X, Y, Z, R1, R2, R3, R4 and R5are as defined herein. Also disclosed are methods of making the compounds and using the compounds for treatment of inflammatory diseases such as arthritis.
    Type: Application
    Filed: November 1, 2017
    Publication date: March 15, 2018
    Applicant: Genentech, Inc.
    Inventors: Benjamin Fauber, James J. Crawford, Sarah M. Bronner, Monique Bodil van Niel, Andrew Cridland, Emanuela Gancia, Christopher Hurley, Jonathan Killen, Stuart Ward
  • PYRIDAZINE DERIVATIVES AS RORc MODULATORS
    Publication number: 20180051010
    Abstract: Compounds of formula I: or pharmaceutical salts thereof, wherein R1, R2, R3 and R4 are as defined herein. Also disclosed are methods of making the compounds and using the compounds for treatment of inflammatory diseases such as arthritis.
    Type: Application
    Filed: November 1, 2017
    Publication date: February 22, 2018
    Applicant: Genentech, Inc.
    Inventors: Benjamin Fauber, Monique Bodil van Niel, Andrew Cridland, Christopher Hurley, Jonathan Killen, Stuart Ward, Paul Winship
  • PYRIDAZINE DERIVATIVES AS RORc MODULATORS
    Publication number: 20150126491
    Abstract: Compounds of the formula I: or a pharmaceutical salt thereof, wherein X, Ar1, R1, R2, R3, R4, R5, R6 and R7 are as defined herein. Also disclosed are methods of making the compounds and using the compounds for treatment of inflammatory diseases such as arthritis.
    Type: Application
    Filed: November 5, 2014
    Publication date: May 7, 2015
    Applicant: Genentech, Inc.
    Inventors: Monique Bodil van Niel, Andrew Cridland, Benjamin Fauber, Alberto Gobbi, Christopher Hurley, David Hurst, Jonathan Killen, Robert Maxey, Stuart Ward
  • 3-pyridylcarbonyl-piperazinylsulfonyl derivatives
    Patent number: 8536183
    Abstract: The present invention relates to novel piperazine derivatives; to processes for their preparation; to pharmaceutical compositions containing the derivatives; and to the use of the derivatives in therapy to treat diseases for which blocking the Cav2.2 calcium channels is beneficial.
    Type: Grant
    Filed: August 7, 2012
    Date of Patent: September 17, 2013
    Assignee: Convergence Pharmaceuticals Limited
    Inventors: Paul John Beswick, Alister Campbell, Andrew Cridland, Robert James Gleave, Jag Paul Heer, Neville Hubert Nicholson, Lee William Page, Sadie Vile
  • 3-PYRIDYLCARBONYL-PIPERAZINYLSULFONYL DERIVATIVES
    Publication number: 20120302746
    Abstract: The present invention relates to novel piperazine derivatives; to processes for their preparation; to pharmaceutical compositions containing the derivatives; and to the use of the derivatives in therapy to treat diseases for which blocking the Cav2.2 calcium channels is beneficial.
    Type: Application
    Filed: August 7, 2012
    Publication date: November 29, 2012
    Inventors: Paul John Beswick, Alister Campbell, Andrew Cridland, Robert James Gleave, Jag Paul Heer, Neville Hubert Nicholson, Lee William Page, Sadie Vile
  • 3-pyridylcarbonyl-piperazinylsulfonyl derivatives
    Patent number: 8288388
    Abstract: The present invention relates to novel piperazine derivatives; to processes for their preparation; to pharmaceutical compositions containing the derivatives; and to the use of the derivatives in therapy to treat diseases for which blocking the Cav2.2 calcium channels is beneficial.
    Type: Grant
    Filed: July 15, 2009
    Date of Patent: October 16, 2012
    Assignee: Convergence Pharmaceuticals Limited
    Inventors: Paul John Beswick, Alister Campbell, Andrew Cridland, Robert James Gleave, Jag Paul Heer, Neville Hubert Nicholson, Lee William Page, Sadie Vile
  • Novel Derivatives
    Publication number: 20100022555
    Abstract: The present invention relates to novel piperazine derivatives; to processes for their preparation; to pharmaceutical compositions containing the derivatives; and to the use of the derivatives in therapy to treat diseases for which blocking the Cav2.2 calcium channels is beneficial.
    Type: Application
    Filed: July 15, 2009
    Publication date: January 28, 2010
    Inventors: Paul John Beswick, Alister Campbell, Andrew Cridland, Robert James Gleave, Jag Paul Heer, Neville Hubert Nicholson, Lee William Page, Sadie Vile